SS-31 (Elamipretide) — Stack & Timing
Educational timing and stacking information based on how SS-31 (Elamipretide) has been studied. Not a prescription. Not medical advice.
This is educational information only. Consult a healthcare provider before starting any supplement.
Stack & Timing Guidance
Educational summary based on how SS-31 (Elamipretide) has been studied and commonly used.
Commonly studied timing
No timing-specific guidance can be derived from the available review literature; SS-31 (Elamipretide) has primarily been studied as a subcutaneous injectable in clinical and preclinical settings, where timing was protocol-driven rather than consumer-directed.
Commonly paired with
Both target mitochondrial electron transport chain efficiency and oxidative stress reduction; combining them may offer complementary support for mitochondrial membrane integrity and ATP production.
MitoQ is a mitochondria-targeted antioxidant similarly designed to reduce mitochondrial ROS, making it mechanistically complementary to SS-31's cardiolipin-stabilizing effects.
NAD+ precursors support mitochondrial biogenesis and sirtuin activity, potentially complementing SS-31's mitochondrial membrane-protective effects in aging contexts.
In the context of dry AMD, lutein and zeaxanthin protect macular photoreceptors from oxidative damage, potentially complementing SS-31's mitochondrial protective mechanisms in retinal cells.
Safety & interactions
SS-31 (Elamipretide) is an investigational peptide not approved as a consumer supplement; it has been administered in clinical trials primarily via subcutaneous injection under medical supervision. The available reviews do not report specific adverse event profiles, and self-administration outside clinical settings is not supported by the evidence base.
Individuals who are pregnant, breastfeeding, have known peptide hypersensitivity, or are taking immunosuppressive or mitochondria-modulating medications should exercise extreme caution; use should only occur under qualified medical supervision given its investigational status.